PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Inclusion Criteria:

* All patients must have cytology/ biopsy proven diagnosis of a mullerian carcinoma, high clinical index of suspicion for ovarian cancer OR triple negative, BRCA mutated breast cancer.
* Patients may not have received prior treatment for breast or ovarian cancer.
* All patients must be of at least 18 years of age.
* ECOG Performance status must be 0,1 or 2.
* Patients must not have received a prior PARP inhibitor
* Adequate organ and marrow function as defined below:
* absolute neutrophil count \>/= 1500/mcL
* Platelets \> /= 100,000 /mcl
* Hemoglobin \>/= 8 g/dl
* Total bilirubin \</= 1.5 x the institutional ULN
* AST, ALT \</= 3 x the institutional ULN
* Creatinine \</= the institutional ULN
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

  * Has not undergone a hysterectomy or bilateral oophorectomy; or
  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
* Patients must be able to swallow and retain oral medications.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment. Subjects must have recovered from prior treatment-related to toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).
* Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.
* Brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Lynparza or other agents used in study.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.